Propofol + Dexmedetomidine
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Delirium
Conditions
Delirium, Cardiac Disease
Trial Timeline
Apr 1, 2011 → Apr 1, 2015
NCT ID
NCT01378741About Propofol + Dexmedetomidine
Propofol + Dexmedetomidine is a pre-clinical stage product being developed by Pfizer for Delirium. The current trial status is completed. This product is registered under clinical trial identifier NCT01378741. Target conditions include Delirium, Cardiac Disease.
What happened to similar drugs?
5 of 13 similar drugs in Delirium were approved
Approved (5) Terminated (3) Active (6)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01378741 | Pre-clinical | Completed |
Competing Products
17 competing products in Delirium
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lemborexant 5 mg + Control (placebo) group | Eisai | Phase 2 | 42 |
| Suvorexant + Placebo | Merck | Phase 3 | 40 |
| Suvorexant 20 mg + Placebo | Merck | Phase 2 | 35 |
| Rivastigmine + Placebo | Novartis | Approved | 35 |
| Rivastigmine prevention of delirium | Novartis | Phase 3 | 40 |
| Rivastigmine transdermal patch + placebo patch | Novartis | Phase 3 | 40 |
| Rivastigmine Patch | Novartis | Approved | 43 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 32 |
| Parecoxib | Pfizer | Approved | 39 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 32 |
| Pregabalin | Pfizer | Phase 3 | 40 |
| Dexmedetomidine + Midazolam | Pfizer | Phase 3 | 47 |
| Dexmedetomidine + Saline placebo | Pfizer | Phase 2/3 | 38 |
| Cyclopofol + Propofol | Haisco Pharmaceutical Group | Approved | 39 |
| Dexmedetomidine + Sodium chloride 0.9% | Baxter | Phase 3 | 37 |
| Dexmedetomidine Hydrochloride Group | Brain Biotech | Approved | 40 |
| Dexmedetomidine sublingual film | BioXcel Therapeutics | Phase 2 | 17 |